Stocks Johnson & Johnson

More

  • NEW YORK, Dec 10- When health insurer Humana Inc reported worse-than-expected quarterly earnings in late 2014- including a 21 percent drop in net income- it softened the blow by immediately telling investors it would make a $500 million share repurchase. It added around two cents to the company's annual earnings per share, allowing Humana to surpass its $7.50...

  • FRANKFURT, Dec 9- European and U.S. drug regulators are looking into whether a defective blood clotting test device affected a trial involving Bayer's top-selling anti-clotting drug Xarelto, hitting the German drugmaker's shares. "Due to the defect it is now thought that the INR device may have impacted the clotting results in some patients in the warfarin...

  • The only stocks in the S&P 500 that matter Wednesday, 9 Dec 2015 | 7:28 AM ET
    Traders work on the floor of the New York Stock Exchange.

    Returns within the S&P 500 are concentrated in a handful of its largest stocks, an alarming trend not seen since the dot-com bust.

  • BERLIN, Dec 9- European and U.S. drug regulators are looking into whether a defective blood-clotting test device affected a trial involving Bayer's blockbuster anti-blood clotting drug Xarelto, hitting the German drugmaker's shares. Bayer and Duke University's Clinical Research Institute, which conducted some of the trial work and which used the device in...

  • This stock can play offense and defense: Technician Monday, 7 Dec 2015 | 12:10 PM ET

    Volatility is in full force ahead of next week's FOMC meeting. Technician Carter Worth points to a "safe" stock for traders to hide out in.

  • *Yellen gives Congress upbeat view on march towards liftoff. Dec 3- U.S. stocks were lower in early trading on Thursday after European Central Bank's minimal rate cut and extended stimulus failed to live up to market expectations. The ECB move comes a day after Federal Reserve Chair Janet Yellen expressed confidence in the U.S. economy and said she was "looking...

  • Traders talk Barclays' bullish pharma call Tuesday, 1 Dec 2015 | 1:54 PM ET

    The "Halftime Report" traders give their top trades of the show.

  • Early movers: AMZN, ALL, YUM, JNJ, T, CC & more Tuesday, 1 Dec 2015 | 7:55 AM ET
    Traders work on the floor of the New York Stock Exchange.

    Some of the names on the move ahead of the open.

  • Nov 30- The U.S. Food and Drug Administration said on Monday it had approved a drug to be sold by Bristol-Myers Squibb Co as a treatment for a form of blood cancer. The FDA said it approved the treatment, Empliciti, to be used in multiple myeloma patients in combination with Celgene Corp's Revlimid and common anti-inflammatory drug dexamethasone.

  • WASHINGTON, Nov 30- The U.S. Supreme Court on Monday rejected an appeal by Covidien LP seeking to restore a $176 million patent infringement verdict against Johnson& Johnson subsidiary Ethicon Inc.. In a separate patent case, the court declined to hear Biolitec AG's challenge to a $70 million contempt finding relating to a patent dispute the company had with...

  • *Guggenheim named Pfizer's lead adviser on $160 bln Allergan deal. *Schwartz has cultivated ties with Pfizer and its CEO over years. His strategy paid off handsomely when Guggenheim was named lead adviser for one of the biggest deals in history- Viagra-maker Pfizer's $160 billion acquisition of Botox-maker Allergan.

  • LONDON, Nov 20- Drug companies have brought a host of expensive new medicines to market in the United States and Europe this year, figures show, another bumper haul for an industry often accused of over-charging. The U.S. Food and Drug Administration has so far approved 38 novel drugs in 2015, more than the 34 that had been cleared by this stage a year ago and just...

  • LONDON, Nov 20- Drug companies have brought a host of expensive new medicines to market in the United States and Europe this year, figures show, another bumper haul for an industry often accused of over-charging. The U.S. Food and Drug Administration has so far approved 37 novel drugs in 2015, more than the 34 that had been cleared by this stage a year ago and just...

  • NEW YORK/ WASHINGTON, Nov 18- Pfizer Inc's talks to acquire Allergan Plc in a $150 billion deal that would see the U.S. drug giant redomicile in Ireland accelerated on Wednesday, as the U.S. Pfizer is negotiating a price of $370 to $380 for each Allergan share, a person familiar with the discussions said, asking not to be identified because the talks are confidential.

  • *Denmark's Genmab scores important win with new cancer drug. Shares in Genmab, already up 130 percent this year, leapt a further 12 percent on news that the drug, which was licensed to Johnson& Johnson in 2012, had won early U.S. approval, lifting Genmab's market value to around $7 billion. Still, with several analysts forecasting peak annual sales for Darzalex of $5...

  • Early movers: HD, WMT, DKS, ANGI, GE, JNJ & more Tuesday, 17 Nov 2015 | 7:52 AM ET
    Traders work on the floor of the New York Stock Exchange.

    Some of the names on the move ahead of the open.

  • Nov 17- Shares in Genmab jumped 11 percent on Tuesday after U.S. regulators approved an experimental blood cancer drug that the Danish biotech company licensed in 2012 to Johnson& Johnson. The U.S. Food and Drug Administration said late on Monday it had approved Darzalex for patients who had already undergone at least three prior standard treatments for...

  • Lightning Round: It's insane how much it went down Tuesday, 10 Nov 2015 | 7:00 PM ET
    Mad Money Lightning Round

    Jim Cramer rattles off his take on caller favorite stocks, including this stock that is down so low it is ridiculous.

  • ORLANDO, Nov 9- Eli Lilly's new diabetes drug Jardiance significantly cut the risk of heart-related death and hospitalization for heart failure in patients with type 2 diabetes who are at high risk for serious heart problems, according to data from a large study presented on Monday. The 3- year trial of more than 7,000 patients caused a sensation in September,...

  • NEW YORK, Nov 8- A few days after joining the board of Atlantic Power, private equity veteran Gilbert Palter said he got a flurry of calls from the energy company's top shareholders, who wanted more than just to wish him well. And they wanted to bend my ear with their own thoughts, "said Palter, co-founder of EdgeStone Capital Partners in Toronto. From JPMorgan Chase& Co...